Avenue Therapeutics, Inc.
General ticker "ATXI" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $937.4K (TTM average)
Avenue Therapeutics, Inc. follows the US Stock Market performance with the rate: 5.8%.
Estimated limits based on current volatility of 8.1%: low 0.76$, high 0.90$
Factors to consider:
- Total employees count: 2 as of 2022
- Top business risk factors: Labor/talent shortage/retention, Dependence on product candidates, Limited operating history, Economic downturns and volatility, System failures and security breaches
- Current price 26.3% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.03$, 3.65$]
- 2025-12-31 to 2026-12-31 estimated range: [0.77$, 2.78$]
Financial Metrics affecting the ATXI estimates:
- Positive: with PPE of -0.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -37.62 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Positive: Investing cash flow per share per price, % of 0 > -0.66
- Negative: negative Industry operating income (median)
- Negative: Shareholder equity ratio, % of 104.68 > 63.39
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
Short-term ATXI quotes
Long-term ATXI plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $8.04MM | $14.54MM | $11.28MM |
| Operating Income | $-8.04MM | $-14.54MM | $-11.28MM |
| Non-Operating Income | $4.44MM | $4.05MM | $-0.41MM |
| R&D Expense | $2.70MM | $10.36MM | $6.64MM |
| Income(Loss) | $-3.60MM | $-10.49MM | $-11.70MM |
| Profit(Loss)* | $-3.55MM | $-10.38MM | $-11.65MM |
| Stockholders Equity | $3.90MM | $1.58MM | $2.80MM |
| Assets | $6.84MM | $1.85MM | $2.67MM |
| Operating Cash Flow | $-7.60MM | $-9.45MM | $-9.03MM |
| Capital expenditure | $0.00MM | $3.00MM | $0.00MM |
| Investing Cash Flow | $0.00MM | $-3.00MM | $0.00MM |
| Financing Cash Flow | $10.54MM | $7.53MM | $9.84MM |
| Earnings Per Share** | $-121.92 | $-73.60 | $-0.90 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.